Functional Electrical Stimulation Cycling
DeviceFES-assisted arm cycling is provided for approximately 40 minutes per session, 5 sessions per week for 2 weeks.
NCT Number: NCT07807176
This study will evaluate the effects of functional electrical stimulation (FES) cycling, cognitive task training, and non-invasive photobiomodulation on cognitive and upper-limb motor performance in adults after stroke. The study includes three stages to identify favorable FES cycling and neuromodulation approaches and to evaluate their combined effects. Participants will complete 10 intervention sessions over 2 weeks. Cognitive and motor outcomes will be assessed before treatment, immediately after treatment, and at 3-month follow-up. Feasibility, tolerance, and adverse events will also be evaluated.
Trial opening soon.
Get Notified20 year–80 year
All sexes
Interventional
Not applicable
This is a three-stage, randomized, sham-controlled study in individuals after stroke. Stage 1 will compare FES cycling alone, FES cycling combined with cognitive task training, and sham FES cycling. Stage 2 will compare photobiomodulation applied to the ear, forehead, and sham stimulation. Stage 3 will evaluate the selected FES cycling and neuromodulation approaches alone and in combination. Participants will complete 10 sessions over 2 weeks. Cognitive, upper-extremity motor, functional, participation, and quality-of-life outcomes will be assessed at baseline, immediately after treatment, and at 3-month follow-up. Feasibility, adherence, tolerance, and adverse events will also be monitored.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
FES-assisted arm cycling is provided for approximately 40 minutes per session, 5 sessions per week for 2 weeks.
Cognitive tasks are performed during FES cycling and progressively target attention, working memory, and executive control.
Photobiomodulation is applied to the outer ear for approximately 20 to 30 minutes.
Photobiomodulation is applied to the forehead for approximately 20 to 30 minutes.
Participants receive the sham FES cycling control condition.
Participants receive the sham photobiomodulation control condition.
The FES cycling condition associated with the most favorable cognitive-motor performance pattern in Stage 1 will be selected for use in Stage 3. The selected protocol will consist of either FES cycling alone or FES cycling combined with cognitive task training.
The photobiomodulation condition associated with the most favorable cognitive-motor performance pattern in Stage 2 will be selected for use in Stage 3. The selected protocol will consist of either transcutaneous auricular photobiomodulation (taPBM) or transcutaneous forehead photobiomodulation (tfPBM).
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The TMT-B assesses executive function and cognitive flexibility. Longer completion times indicate poorer executive function and cognitive flexibility.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The IED assesses set-shifting ability and cognitive flexibility. Fewer errors indicate better performance.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The RVP assesses sustained attention. Higher accuracy indicates better sustained attention.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The Digit Span Test assesses working memory and sustained attention. Higher span scores indicate stronger working memory and sustained attention.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The FMA-UE assesses upper-extremity motor control. Scores range from 0 to 66, with higher scores indicating better motor control.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The ARAT assesses upper-limb functional performance. Scores range from 0 to 57, with higher scores indicating better upper-limb function.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The MoCA assesses cognitive functioning across domains including attention, executive function, memory, and visuospatial skills. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The TMT-A assesses processing speed and attention. Longer completion times indicate poorer processing speed and attention.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The SDMT assesses processing speed. More correct responses indicate better processing speed.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The SWM assesses working memory. Fewer errors indicate better working memory performance.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The PAL assesses visual learning. Fewer errors indicate better visual learning performance.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The MAS assesses muscle spasticity. Scores range from 0 to 4, with higher scores indicating greater spasticity.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
Grip and pinch dynamometry measures upper-extremity muscle strength. Higher force output indicates greater muscle strength.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The BBT assesses gross manual dexterity. More blocks transferred indicate better gross manual dexterity.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The 9HPT assesses fine motor coordination. Shorter completion times indicate better fine motor coordination.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The MAL assesses use of the affected arm in daily activities and perceived quality of movement. Scores range from 0 to 5, with higher ratings indicating greater daily arm use and better movement quality.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The ABILHAND Questionnaire assesses perceived manual ability in daily activities. Higher logit scores indicate better perceived manual ability.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The FIM assesses functional independence. Scores range from 18 to 126, with higher scores indicating greater functional independence.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The SIS assesses the impact of stroke on functional recovery. Domain scores range from 0 to 100, with higher scores indicating better functional recovery.
Time frame: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
The SS-QOL assesses stroke-specific health-related quality of life. Higher scores indicate better health-related quality of life.
Contact information is provided by the study sponsor or research team.
Chang Gung Memorial Hospital
Other
Exploratory Evaluation of Neuromodulation Combined With Dual Functional Electrical Stimulation Cycling and Cognitive Task Training on Cognitive-Motor Performance in Individuals After Stroke
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07805694
Brain Diseases, Cardiovascular Diseases
Villeurbanne, France
View Trial DetailsNCT07802470
Brain Diseases, Cardiovascular Diseases
Chicago, Illinois, United States
View Trial DetailsNCT07719374
Brain Diseases, Cardiovascular Diseases
View Trial DetailsNCT07799987
Behavior, Brain Diseases
Gainesville, Florida, United States
View Trial Details